FILE - Photograph of a Novavax building located in Rockville, Maryland. (Photo credit should read PAUL J.
RICHARDS/AFP via Getty Images)LOS ANGELES - Researchers have reported positive results from recent studies of a COVID-19 vaccine candidate by the biotech company Novavax, which is currently among a group of vaccine producers that is in the first round of safety tests in humans — known as phase 1 trials.
According to Novavax, 131 healthy healthy adults aged 18-59 were enrolled in the clinical trails, which evaluated two doses of the company’s COVID-19 vaccine.
Researchers said 100% of the trial volunteers who were administered a vaccine developed critical neutralizing antibodies that help fight against SARS-CoV-2, the virus that causes.